Mark Kozloff to Breast Neoplasms
This is a "connection" page, showing publications Mark Kozloff has written about Breast Neoplasms.
Connection Strength
0.230
-
An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol. 2010 Jul; 21(7):1436-1441.
Score: 0.130
-
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. BMC Cancer. 2014 Mar 07; 14:166.
Score: 0.044
-
SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol. 2010 Dec; 21(12):2370-2376.
Score: 0.034
-
Platinol (CDDP) and continuous intravenous infusion 5-fluorouracil in refractory stage IV breast cancer: a phase II study. Cancer Invest. 1990; 8(3-4):335-8.
Score: 0.008
-
Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy. Cancer. 1983 Feb 01; 51(3):381-4.
Score: 0.005
-
Multimodality therapy of stage III adenocarcinoma of the breast. J Surg Oncol. 1983 Jan; 22(1):5-8.
Score: 0.005
-
Prognostic value of the estrogen receptor level in pathologic stage I and II adenocarcinoma of the breast. J Surg Oncol. 1982 Feb; 19(2):119-21.
Score: 0.005